Hossein Taghizadeh
- 4.7 Excellent • 152 reviews
- 7 years of experience
- Austria, Vienna, Wiener Privatklinik
Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.
Professor Drach is a specialist in oncology with a PhD from the Medical University of Vienna. He has experience in research, internal medicine, hematologic oncology, nutrition, and lifestyle in cancer. He is the Director of the Josefstadt Private Clinic in Vienna and a member of the Board of Directors of the Austrian Society of Hematology and Oncology. He has published more than 120 scientific papers and given more than 200 lectures/presentations.
Assoc. Prof. Priv.-Doz. Dr. Gerald Prager is a Vienna-based specialist in hematology and internal oncology with about 17 to 19 years of experience. He graduated from the Medical University of Vienna. From 2006 to 2011, he completed his residency and fellowship in hematology and oncology there. In 2011, he was a Visiting Professor at the Norris Comprehensive Cancer Center (USC). In 2012, he became an Associate Professor at MedUni Vienna.
He leads the Precision Medicine in Cancer Unit. His work focuses on colorectal cancer, precision oncology, tumor angiogenesis, and predictive biomarker assessment. He is a permanent reviewer for leading journals, including Blood and the European Journal of Clinical Investigation.
Univ.-Prof. Dr. Heinz Gisslinger is a leading hematologist and internal oncologist at the Medical University of Vienna and the Confraternität Private Clinic Josefstadt. He helped found the Laboratory for Myeloproliferative Neoplasms. He is Program Director for Myeloproliferative Neoplasms and leads clinical and translational research.
He pioneered interferon therapy for myeloproliferative neoplasms (MPNs). He first used it clinically in the 1980s and has advanced it for more than four decades. His expertise includes polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic myeloid leukemia, and multiple myeloma.